DexCom Inc (DXCM)

Currency in USD
84.46
-4.02(-4.54%)
Closed·
83.19-1.27(-1.50%)
·
DXCM is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
83.3290.25
52 wk Range
54.1192.59
Key Statistics
Prev. Close
88.48
Open
89.58
Day's Range
83.32-90.25
52 wk Range
54.11-92.59
Volume
4.56M
Average Vol. (3m)
4.39M
1-Year Change
42.4764%
Book Value / Share
6.72
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DXCM Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
98.15
Upside
+16.21%
Members' Sentiments
Bearish
Bullish
ProTips
Management has been aggressively buying back shares

DexCom Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy

Analyst Ratings

26 Buy
3 Hold
0 Sell
Ratings:
29 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 98.15
(+16.21% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
UBS
Buy107.00+26.69%102.00MaintainOct 30, 2026
JPMorgan
Hold85.00+0.64%82.00MaintainOct 30, 2026
StoneX
Buy93.00+10.11%82.00MaintainOct 30, 2026
Canaccord
Buy97.00+14.85%90.00MaintainOct 30, 2026
Barclays
Buy120.00+42.08%115.00MaintainOct 30, 2026

DexCom Inc SWOT Analysis


Quality vs. Margins
Discover how Dexcom's quality enhancement initiatives create near-term profitability pressures while potentially building long-term competitive advantages
Competitive Battlefield
Intensifying rivalry in Type 1 and intensive Type 2 diabetes markets threatens market share as new entrants and established players introduce alternative solutions
Analyst Targets
Price targets range from $71 to $80, reflecting mixed analyst sentiment on the company's ability to navigate competitive pressures and margin challenges
Q4 Performance Shines
Dexcom exceeded Q4 sales and earnings expectations, demonstrating operational strength in diabetes management technology despite market uncertainties
Read full SWOT analysis

DexCom Inc Earnings Call Summary for Q3/2026

  • Dexcom Q3 EPS of $0.73 beat estimates by 9%, revenue rose 11% YoY to $1.34B; gross margin improved 380bps to 65.1%, the highest since late 2022.
  • Company raised FY 2026 revenue guidance to $5.20B-$5.25B (12-13% growth), operating margin to ~24%, and adjusted EBITDA margin to ~32%.
  • U.S. revenue grew 14% to $970M driven by strong type 2 diabetes adoption; international sales up 5% to $375M, impacted by tough prior-year comparisons.
  • G7 15 Day expected to reach 50% of U.S. customers by year-end; G8 launch targeted for late 2027/early 2028; Dexcom Direct service launching early 2027.
  • Completed $1B share buyback program and authorized another $1B; generated $900M+ free cash flow through Q3 with $1.8B cash on hand.
Last Updated: 10/29/2026, 05:41 PM
Read Full Transcript
DexCom investor slides for Q3/2026
Dexcom Q3 2026 slides
Last Update: Oct 29, 2026
See full investor slides

Earnings

Latest Release
Oct 29, 2026
EPS / Forecast
0.73 / 0.67
Revenue / Forecast
1.34B / 1.33B
EPS Revisions
Last 90 days

DXCM Income Statement

Compare DXCM to Peers and Sector

Metrics to compare
DXCM
Peers
Sector
Relationship
P/E Ratio
31.8x21.6x−0.2x
PEG Ratio
0.75−1.110.00
Price / Book
12.4x2.7x2.6x
Price / LTM Sales
6.2x3.0x2.8x
Upside (Analyst Target)
16.2%19.3%62.7%
Fair Value Upside
Unlock−2.8%8.0%Unlock

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
217.01M57.51%19.20B
Other Institutional Investors
177.99M42.49%15.75B
Public Companies & Retail Investors
0.000.00%0.00
Total
395M100.00%34.95B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.10.13%38,244,1373,383,841
Vanguard Capital Management, LLC7.27%27,426,9312,426,735

People Also Watch

212.74
TER
-15.24%
466.53
STX
-16.25%
656.39
MU
-17.46%
181.60
NVDA
-9.26%
356.10
APP
+31.04%

FAQ

What Is the DexCom (DXCM) Stock Price Today?

The DexCom stock price today is 84.46 USD.

What Stock Exchange Does DexCom Trade On?

DexCom is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for DexCom?

The stock symbol for DexCom is "DXCM."

What Is the DexCom Market Cap?

As of today, DexCom market cap is 33.00B USD.

What Is DexCom's Earnings Per Share (TTM)?

The DexCom EPS (TTM) is 2.59.

When Is the Next DexCom Earnings Date?

DexCom will release its next earnings report on Feb 11, 2027.

From a Technical Analysis Perspective, Is DXCM a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has DexCom Stock Split?

DexCom has split 1 times.

How Many Employees Does DexCom Have?

DexCom has 11050 employees.

What is the current trading status of DexCom (DXCM)?

As of Nov 05, 2026, DexCom (DXCM) is trading at a price of 84.46 USD, with a previous close of 88.48 USD. The stock has fluctuated within a day range of 83.32 USD to 90.25 USD, while its 52-week range spans from 54.11 USD to 92.59 USD.

What Is DexCom (DXCM) Price Target According to Analysts?

The average 12-month price target for DexCom is 98.15 USD, with a high estimate of 120 USD and a low estimate of 79 USD. 26 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +16.21% Upside potential.

What Is the DXCM Premarket Price?

DXCM's last pre-market stock price is 89.75 USD. The pre-market share volume is 27,920.00, and the stock has decreased by 1.27, or 1.44%.

What Is the DXCM After Hours Price?

DXCM's last after hours stock price is 83.19 USD, the stock has decreased by -1.27, or -1.50%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.